Rubini Maya Kannangara

Title: Rubini Maya Kannangara: Innovator in Opioid Production

Introduction

Rubini Maya Kannangara is a notable inventor based in Copenhagen, Denmark. He has made significant contributions to the field of biochemistry, particularly in the area of opioid production. His innovative work focuses on the demethylation of reticuline, a crucial step in synthesizing opioids.

Latest Patents

Rubini holds a patent for the invention titled "Demethylation of reticuline and derivatives thereof with fungal cytochrome P450." This invention relates to recombinant host cells that express one or more genes encoding a cytochrome P450 enzyme capable of N-demethylating and/or O-demethylating reticuline and/or its derivatives. The methods described in the patent involve cultivating these recombinant host cells in a culture medium under specific conditions to produce N-demethylated and/or O-demethylated reticuline and its derivatives. This innovation is particularly valuable as it provides access to naturally unavailable and chemically difficult-to-produce starting materials for opioids.

Career Highlights

Rubini is currently associated with River Stone Biotech LLC, where he continues to advance his research and development efforts. His work has garnered attention for its potential applications in the pharmaceutical industry, especially in the production of essential compounds for pain management.

Collaborations

Rubini collaborates with talented individuals in his field, including Markus Schwab and Sumire Honda Malca. Their combined expertise contributes to the innovative environment at River Stone Biotech LLC.

Conclusion

Rubini Maya Kannangara's contributions to the field of biochemistry, particularly in opioid production, highlight the importance of innovation in addressing complex challenges in medicine. His patent and ongoing research efforts are paving the way for advancements in the pharmaceutical industry.